

#2/9/01 6/11/01

SHEET 1 OF 6


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. NIH061.1CP1C2	APPLICATION NO. -unknown- 09/756,411
	APPLICANT Lori et al.	
	FILING DATE herewith	GROUP Art Unit 1623

JCS64 U.S. PTO  
 09/756411  
 01/08/01

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
**	1	4,708,818	11/24/87	Montagnier et al.			
**	2	5,026,687	06/25/91	Yerehoan et al.			
**	3	5,110,600	05/05/92	Green			
**	4	5,300,050	04/05/94	Rubinstein et al.			
**	5	6,046,175	04/04/00	Lori et al.			
**	6	6,093,702	07/25/00	Malley et al.			
**	7	5,521,161	05/28/96	Malley et al.			
**	8	5,736,526	04/07/98	Malley et al.			
**	9	5,736,527	04/07/99	Malley et al.			

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
L**	10	EP 0 206 497	12/30/86	EPO				
**	11	WO 87/01284	03/12/87	WIPO				
me	12	WO 92/08699	05/29/92	WIPO				
me	13	WO 93/12782	07/08/93	WIPO				
me	14	WO 93/23368	11/25/93	WIPO				
me	15	WO 94/27590	12/08/94	WIPO				
me	16	WO 95/17899	07/06/95	WIPO				

\*\* Duplicate of reference already of record on a PTO-892.

EXAMINER  L. E. Crane	DATE CONSIDERED 06/12/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. NIH061.1CP1C2	APPLICATION NO. <del>unknown</del> 09/756,411
	APPLICANT Lori et al.	
	FILING DATE herewith	GROUP <b>Art Unit 1623</b> <del>unknown</del>

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
Jre	17	Albert et al., <i>Experimental Cell Research</i> , 179: 417-428, 1988,
	!	"Deoxyadenosine Toxicity and Cell Cycle Arrest in Hydroxyurea-Resistant S49 T-Lymphoma Cells."
Jre	18	Altman, L.K., <i>New York Times</i> , p. 38, Sunday, September 17, 1995,
		"Study Challenges AZT Role as the Chief Drug for H.I.V."
Jre	19	Balzarini et al., <i>Molecular Pharmacology</i> , 32: 798-806, 1987,
	!	"2', 3'-Dideoxycytidine: Regulation of its Metabolism and Anti-retroviral Potency by Natural Pyrimidine Nucleosides and by Inhibitors of Pyrimidine Nucleotide Synthesis."
**	<del>20</del>	<del>Barre-Sinoussi et al., <i>Science</i>, 220: 868-871, 1983,</del>
		"Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)."
Jre	21	Biron et al., <i>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</i> , 10(1): 36-40, 1995,
	!	"Anti-HIV Activity of the Combination of Didanosine and Hydroxyurea in HIV-1-Infected Individuals."
**	22	Bukrinsky et al., <i>Science</i> , 254: 233-237, 1991,
		"Quiescent T Lymphocytes as an Inducible Virus Reservoir in HIV-1 Infection."
**	23	<del>Busse et al., <i>AIDS Res. Human Retroviruses</i>, 6(9): 1139-1146, 1990,</del>
		"Cellular Pharmacology and Anti-HIV Activity of 2', 3'-Dideoxyguanosine."
**	24	<del>Centers for Disease Control, <i>Morbidity Mortality Weekly Report</i>, 30(25): 305-308, July 3, 1981,</del>
		"Kaposi's Sarcoma and <i>Pneumocystis</i> Pneumonia Among Homosexual Men."
**	25	<del>Chew et al., <i>Nature</i>, 361: 650-654, 1993,</del>
		"Use of Evolutionary Limitations of HIV-1 Multidrug Resistance to Optimize Therapy."
Jre	26	Coffin, H., <i>Fundamental Virology 2nd Edition</i> , pp. 545-708, Raven Press, New York, 1991,
	!	"Retroviridae and Their Replication."
**	27	Fauci, <i>Science</i> , 239: 617-622, 1988,
		"The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis."
**	28	Fauci, <i>Science</i> , 262: 1011-1018, 1993,
		"Multifactorial Nature of Human Immunodeficiency Virus Disease: Implications for Therapy."
**	29	<del>Fearino et al., <i>Antiviral Chemistry &amp; Chemotherapy</i>, 4(1): 55-63, 1993,</del>
		"Prevention of Activation of HIV-1 by Antiviral Agents in OM-10.1 Cells."
Jre	30	Fischl, <i>AIDS Clin. Rev.</i> , 94: 167-187, 1993,
	!	"Treatment of HIV Disease in 1993/1994."
	**	Duplicate of reference already cited on a PTO-892.

EXAMINER <i>L. E. Crane</i> L. E. Crane	DATE CONSIDERED 06/12/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NIH061.1CP1C2	APPLICATION NO. <del>unknown</del> 09/756,411
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Lori et al.	
		FILING DATE herewith	GROUP Art Unit 1623 <del>unknown</del>

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
**	31 <del>Fox et al., J. Infectious Diseases, 164: 1051-1057, 1991,</del> "Lymphoid Germinal Centers are Reservoirs of Human Immunodeficiency."
me	32 Gao, <i>Aids Research and Human Viruses</i> , 10(1): Supp. 3, Abstract No. 355, 1994, ! "Mechanisms of the Enhanced Anti-HIV-1 Activities of 2', 3'-Dideoxynucleoside Analogs by Hydroxyurea."
me	33 Gao et al., <i>Clinical Research</i> , 42(2): 280A, 1994, ! "Anti-HIV-1 Activity of Hydroxyurea in Combination with 2', 3'-Dideoxynucleosides."
me	34 Gao et al., <i>Mol. Pharmacol.</i> , 46(4): 767-772, 1994, ! "Anti-Human Immunodeficiency Virus Type 1 Activity of Hydroxyurea in Combination with 2', 3'-Dideoxynucleosides."
**	35 <del>Gao et al., Proc. Natl. Acad. Sci. USA, 90, 8925-8928, October 1993,</del> "Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication."
me	36 Goulaouic et al., <i>C.R. Acad. Sci. Paris</i> , 317: 430-436, 1994, ! "Potentiation of 2', 3'-Dideoxycytidine (ddc) by Hydroxyurea and Thymidine on the Moloney Murine Leukemia Virus (MoMLV) Early Replicative Steps."
me	37 Goulaouic et al., <i>Virology</i> , 200: 87-97, 1994, ! "Exogenous Nucleosides Promote the Completion of MoMLV DNA Synthesis in GO-Arrested Balb c/3T3 Fibroblasts."
me	38 Hao et al., <i>Molecular Pharmacology</i> , 34:431-435, 1988, ! "Factors Determining the Activity of 2', 3'-Dideoxynucleosides in Suppressing Human Immunodeficiency Virus In Vitro."
**	39 <del>Hirsch et al., N. Engl. J. Medicine, 328(23): 1686-1695, 1993,</del> "Therapy for Human Immunodeficiency Virus Infection."
me	40 Huber et al., <i>J. of Biological Chemistry</i> , 264(8): 4669-4678, 1989, ! "Human Immunodeficiency Virus I Reverse Transcriptase."
me	41 Hubscher, H., <i>Experientia</i> , 39(1): 1-25, 1983, ! "DNA Polymerases in Prokaryotes and Eukaryotes: Mode of Action and Biological Implications."
me	42 Ji et al., <i>Mol. Gen. Genet.</i> , 226: 257-264, 1991, ! "Analysis of Mutagenesis Induced by a Thermolabile T4 Phage Deoxycytidylate Hydroxymethylase Suggests Localized Deoxyribonucleotide Pool Imbalance."
**	43 <del>Karlsson et al., Eur. J. Biochem, 186: 689-694, 1989,</del> "Hydroxyurea increases the phosphorylation of 3'-fluorothymidine and 3'-azidothymidine in CEM cells."
me	44 Kati et al., <i>J. of Biological Chemistry</i> , 267(36): 25988-25997, 1992, ! "Mechanism and Fidelity of HIV Reverse Transcriptase."

\*\* Duplicate of reference already of record on a PTO-892.

EXAMINER <i>me</i> L. E. Crane	DATE CONSIDERED 06/12/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

! Month of publication data is unavailable for this reference.

COPY FOR [ ] File [ ] Applicant

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NIH061.1CP1C2	APPLICATION NO. <del>UNKNOWN</del> 09/756,411
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Lori et al.	
		FILING DATE herewith	GROUP Art Unit 1623 <del>unknown</del>

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
Jre	45 Langreth, <i>The Wall Street Journal</i> , p. B12, November 21, 1995, "FDA Gives Approval to Glaxo, Sequus to Market Separate AIDS Therapies."
**	46 <del>Licastro et al., <i>Biochem. Biophys. Res. Comm.</i>, 132(3): 929-933, 1985,</del> "Inhibition of Polymerases- $\alpha$ and - $\beta$ Completely Blocks DNA Repair Induced by UV Irradiation in Cultured Mouse Neuronal Cells."
Jre	47 Lien, <i>Progress in Drug Research</i> , 31: 101-126, 1987, "Ribonucleotide reductase inhibitors as anticancer and antiviral agents."
Jre	48 Lori et al., <i>Antiviral Res.</i> , Vol. 23, Supp. 1, page 63, 1994, "Hydroxyurea Inhibits HIV-1 Replication by Inducing Low dNTP Levels. A Cellular Enzyme as a Target to Inhibit HIV-1."
Jre	49 Lori et al., <i>J. of Virol.</i> , 66(8): 5067-5074, 1992, "Viral DNA Carried by Human Immunodeficiency Virus Type 1 Virions."
Jre	50 Lori et al., <i>International Conference on Aids</i> , 10(1): 8, Abstract No. 007b, 1994 "Hydroxyurea as a Novel Potent Inhibitor of HIV-1 Replication."
**	51 <del>Lori et al., <i>Science</i>, 266(5186): 801-805, 1994,</del> "Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus Type 1 Replication."
Jre	52 Malley et al., <i>The Lancet</i> , 343(8908): 1292, 1994, "Suppression of HIV Production in Resting Lymphocytes by Combining Didanosine and Hydroxamate Compounds."
Jre	53 Malley, <i>Proc. Nat. Acad. Sci. USA</i> , 91(23): 11017-11021, November 1994, "Synergistic Anti-Human Immunodeficiency Virus Type 1 Effect of Hydroxamate Compounds with 2', 3'-Dideoxyinosine in Infected Resting Human Lymphocytes."
**	54 <del>Marquez et al., <i>J. Med. Chem.</i>, 33(3): 978-985, 1990,</del> "Acid-Stable 2'-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV."
Jre	55 Matsumoto et al., <i>The Journal of Immunology</i> , 131(6): 2762-2766, 1983, "Inhibition of RNA Synthesis by Deoxyadenosine Plus Deoxycytosine in Resting Lymphocytes."
Jre	56 McCune et al., <i>Cell</i> , 53: 55-67, 1988, "Endoproteolytic Cleavage of gp160 is Required for the Activation of Human Immunodeficiency Virus."
Jre	57 Medina et al., <i>Antimicrobial Agents and Chemotherapy</i> , 36(5): 1127-1130, 1992, "Ganciclovir Antagonizes the Anti-Human-Immunodeficiency Virus Type 1 Activity of Zidovudine and Didanosine In Vitro."
Jre	58 Meyerhans et al., <i>Journal of Virology</i> , 68(1): 535-540, 1994, "Restriction and Enhancement of Human Immunodeficiency Virus Type 1 Replication by Modulation of Intracellular Deoxynucleosides Triphosphate Pools."

EXAMINER

J E Crane

L. E. Crane

DATE CONSIDERED

06/12/01


\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NIH061.1CP1C2	APPLICATION NO. <del>UNKNOWN</del> 09/756,411
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Lori et al.	
		FILING DATE herewith	GROUP Art Unit 1623 <del>UNKNOWN</del>

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
<i>Me</i>	59	Meyerhans et al., <i>VIII International Conference on AIDS/III STD World Congress</i> , 2: A22-2118, July 1992, "The Intracellular Nucleotide Pool Effects HIV Replication."
<i>Me</i>	60	<i>New York Times</i> , p. B19, November 24, 1995, "Study Puts Risk of H.I.V. in Young U.S. Men at 1 in 92."
**	<del>61</del>	<del>Pauwels et al., <i>J. Virological Methods</i>, 20: 309-321, 1988, "Rapid and Automated Tetrazolium-Based Colorimetric Assay for the Detection of Anti-HIV Compounds."</del>
<i>Me</i>	62	Pegoraro et al., <i>Experimental Cell Res.</i> , 68: 283-290, 1971, "Thymidine Kinase, Deoxycytidine Kinase and Deoxycytidylate Deaminase Activities in Phytohaemagglutinin Stimulated Human Lymphocytes."
<i>Me</i>	63	Perno et al., <i>J. of Exp. Medicine</i> , 168: 1111-1125, 1988, "Inhibition of Human Immunodeficiency Virus (HIV-1/HTLV-III <sub>g</sub> -L) Replication in Fresh and Cultured Human Peripheral Blood Monocytes/Macrophages by Azidothymidine and Related 2', 3'-Dideoxynucleosides."
<i>Me</i>	64	Popovic et al., <i>Science</i> , 224: 467-500, 1984, "Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-Aids."
<i>Me</i>	65	Robinson, W., <i>Fundamental Virology 2nd Edition</i> , pp. 989-1021, Raven Press, New York, 1991, "Hepadnaviridae and Their Replication."
**	<del>66</del>	<del>Root-Bernstein, R.S., <i>Genetic Engineering News</i>, pp. 4-6, September 1, 1992, "AIDS is Moore than HIV: Part I."</del>
**	<del>67</del>	<del>Root-Bernstein, R.S., <i>Genetic Engineering News</i>, pp. 4-5, September 15, 1992, "AIDS is Moore than HIV: Part II."</del>
<i>Me</i>	68	Safrin et al., <i>Journal of Medical Virology</i> , Supplement 1, pp. 146-149, 1993, "Potential for Combined Therapy with 348U87, a Ribonucleotide Reductase Inhibitor, and Acyclovir as Treatment for Acyclovir-Resistant Herpes Simplex Virus Infection."
**	<del>69</del>	<del>Schnittman et al., <i>Science</i>, 245: 305-308, 1989, "The Reservoir for HIV-1 in Human Peripheral Blood is a T Cell that Maintains Expression of CD4."</del>
**	<del>70</del>	<del>Schoofs, <i>New York Times Magazine</i>, pp. 32-35, June 21, 1998, "The Berlin Patient."</del>
**	<del>71</del>	<del>Sigma Chemical Company, <i>catalog</i>, St. Louis, MO, pp. 321 and 341-342, 1992, "Biochemicals/Organic Compounds for Research and Diagnostic Reagents."</del>
<i>Me</i>	72	Simonelli et al., <i>European Aids Clinical Society, Book of Abstracts</i> , September 1995, "Hydroxyurea as an Antiretroviral Drug in HIV Infected Patients: Clinical, Immunological and Virological Evaluation."

EXAMINER	<i>L. E. Crane</i> L. E. Crane	DATE CONSIDERED	06/12/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

\*\* Duplicate of reference already of record on a PTO-892.  
! Month of publication data is unavailable for this reference.

EXAMINER	L. E. Crane 	DATE CONSIDERED	06/12/01
<p><b>*EXAMINER:</b> INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>			